SGI Stock Analysis: Somnigroup International | NYSE
Furnishings, Fixtures & Appliances | NYSE, USA | Market Cap: 15.054m USD | 12M Return: -1.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 154M
EPS Trend: 83.9%
Qual. Beats: 0
Rev. Trend: 86.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Somnigroup International Inc. (NYSE: SGI), formerly known as Tempur Sealy International, is a vertically integrated bedding company that designs, manufactures, distributes, and retails mattresses, foundations, adjustable bases, pillows, and related accessories. The company markets its products under a portfolio of well-known brands, including Tempur-Pedic, Sealy, Stearns & Foster, and Sleepys, and operates retail banners such as Mattress Firm, Dreams, Tempur-Pedic retail stores, and SOVA across the United States and internationally.
The company sells through a multi-channel distribution network that includes company-owned stores, e-commerce platforms, and call centers, alongside third-party retailers serving distribution, hospitality, and healthcare customers. In addition to its direct operations, Somnigroup licenses its Sealy, Tempur, and Stearns & Foster brands, along with related technology and trademarks, to other manufacturers. Headquartered in Dallas, Texas and tracing its origins to 1846, the company operates within the consumer discretionary sector and combines brand ownership, manufacturing, and retail to reach a broad customer base.
- Mattress Firm same-store sales accelerate North American segment growth
- Tempur-Pedic premium brand demand supports pricing power and margins
- US housing slowdown pressures bedding industry replacement cycle demand
| Net Income: 521.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.50 > 1.0 |
| NWC/Revenue: -4.70% < 20% (prev -5.03%; Δ 0.33% < -1%) |
| CFO/TA 0.08 > 3% & CFO 940.2m > Net Income 521.4m |
| Net Debt (8.41b) to EBITDA (1.21b): 6.95 < 3 |
| Current Ratio: 0.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (212.6m) vs 12m ago 6.89% < -2% |
| Gross Margin: 44.37% > 18% (prev 42.05%; Δ 2.33% > 0.5%) |
| Asset Turnover: 67.11% > 50% (prev 47.19%; Δ 19.92% > 0%) |
| Interest Coverage Ratio: 3.50 > 6 (EBIT TTM 934.2m / Interest Expense TTM 266.6m) |
| A: -0.03 (Total Current Assets 1.25b - Total Current Liabilities 1.61b) / Total Assets 11.5b |
| B: 0.34 (Retained Earnings 3.90b / Total Assets 11.5b) |
| C: 0.08 (EBIT TTM 934.2m / Avg Total Assets 11.4b) |
| D: 0.38 (Book Value of Equity 3.15b / Total Liabilities 8.38b) |
| Altman-Z'' = 1.84 = BBB |
| DSRI: 0.69 (Receivables 339.1m/341.8m, Revenue 7.67b/5.35b) |
| GMI: 0.95 (GM 42.05% / 44.37%) |
| AQI: 1.02 (AQ_t 0.64 / AQ_t-1 0.63) |
| SGI: 1.44 (Revenue 7.67b / 5.35b) |
| TATA: -0.04 (NI 521.4m - CFO 940.2m) / TA 11.5b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of July 28, 2026, the stock is trading at USD 72.91 with a total of 2,152,642 shares traded. Over the past week, the price has changed by +3.71%, over one month by -6.71%, over three months by -8.10% and over the past year by -1.70%.
Current recommended Stop Loss: 69.40 (which is 4.8% or 1.2 ATR below the current price).
Somnigroup International has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy SGI.
- StrongBuy: 7
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 97.3 | 33.4% |
P/E Trailing = 28.624
P/E Forward = 22.4719
P/S = 1.9618
P/B = 4.7829
P/EG = 0.8336
Revenue TTM = 7.67b USD
EBIT TTM = 934.2m USD
EBITDA TTM = 1.21b USD
Long Term Debt = 4.44b USD (from longTermDebt, last quarter)
Short Term Debt = 512.8m USD (from shortTermDebt, last quarter)
Debt = 8.52b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.99b
Net Debt = 8.41b USD (calculated: Debt 8.52b - CCE 110.8m)
Enterprise Value = 23.5b USD (15.1b + Debt 8.52b - CCE 110.8m)
Interest Coverage Ratio = 3.50 (Ebit TTM 934.2m / Interest Expense TTM 266.6m)
EV/FCF = 31.85x (Enterprise Value 23.5b / FCF TTM 736.8m)
FCF Yield = 3.14% (FCF TTM 736.8m / Enterprise Value 23.5b)
FCF Margin = 9.60% (FCF TTM 736.8m / Revenue TTM 7.67b)
Net Margin = 6.79% (Net Income TTM 521.4m / Revenue TTM 7.67b)
Gross Margin = 44.37% ((Revenue TTM 7.67b - Cost of Revenue TTM 4.27b) / Revenue TTM)
Gross Margin QoQ = 43.61% (prev 44.93%)
Tobins Q-Ratio = 2.03 (Enterprise Value 23.5b / Total Assets 11.5b)
Interest Expense / Debt = 3.13% (Interest Expense 266.6m / Debt 8.52b)
Taxrate = 21.81% (145.6m / 667.6m)
NOPAT = 730.5m (EBIT 934.2m * (1 - 21.81%))
Current Ratio = 0.78 (Total Current Assets 1.25b / Total Current Liabilities 1.61b)
Debt / Equity = 2.71 (Debt 8.52b / totalStockholderEquity, last quarter 3.15b)
Debt / EBITDA = 6.95 (Net Debt 8.41b / EBITDA 1.21b)
Debt / FCF = 11.41 (Net Debt 8.41b / FCF TTM 736.8m)
Total Stockholder Equity = 3.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.56% (Net Income 521.4m / Total Assets 11.5b)
RoE = 17.26% (Net Income TTM 521.4m / Total Stockholder Equity 3.02b)
RoCE = 12.53% (EBIT 934.2m / Capital Employed (Equity 3.02b + L.T.Debt 4.44b))
RoIC = 7.07% (NOPAT 730.5m / Invested Capital 10.3b)
WACC = 7.21% (E(15.1b)/V(23.6b) * Re(9.90%) + D(8.52b)/V(23.6b) * Rd(3.13%) * (1-Tc(0.22)))
Discount Rate = 9.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.75 | Cagr: 8.16%
[DCF] Terminal Value 77.97% ; FCFF base≈663.2m ; Y1≈760.3m ; Y5≈1.12b
[DCF] Fair Price = 40.07 (EV 16.8b - Net Debt 8.41b = Equity 8.43b / Shares 210.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 83.87 | EPS CAGR: 6.24% | SUE: 0.65 | # QB: 0
Revenue Correlation: 86.72 | Revenue CAGR: 23.21% | SUE: -0.01 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.57 | Chg30d=+1.02% | Revisions=-62% | Analysts=10
EPS next Quarter (2026-09-30): EPS=1.13 | Chg30d=-0.44% | Revisions=-10% | Analysts=10
EPS current Year (2026-12-31): EPS=3.15 | Chg30d=-0.23% | Revisions=-42% | GrowthEPS=+16.6% | GrowthRev=+4.4%
EPS next Year (2027-12-31): EPS=3.90 | Chg30d=-0.23% | Revisions=-55% | GrowthEPS=+23.8% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: -54% (up=7, down=27)